Top

World Journal of Urology

Published in:

Open Access 01-08-2011 | Original Article

Effect of parathyroid hormone on hypogonadism induced bone loss of proximal femur of orchiectomized rat

Authors: M. Tezval, G. Serferaz, T. Rack, L. Kolios, S. Sehmisch, U. Schmelz, H. Tezval, K. M. Stuermer, E. K. Stuermer

Published in: World Journal of Urology | Issue 4/2011

Abstract

Purpose

Management of hypogonadism-induced osteoporosis in elderly men is still a challenge. We investigated the short-term effects of parathyroid hormone (PTH) treatments on strength, micro-architecture, and mineral density of trochanteric region of orchiectomized rat femur.

Methods

Eight-month-old male Sprague–Dawley rats (n = 44) were divided into two groups: (1) orchiectomized (ORX) and (2) sham group. Twelve weeks after orchiectomy, half of the orchiectomized animals were treated with daily subcutaneously injected PTH (0.040 mg/kg/BW) (ORX-PTH) for 5 weeks. The other half remained untreated (ORX). The sham-operated group was divided and treated in the same way (sham, sham-PTH). After 5 weeks, both femurs were excised for biomechanical and histomorphometric analysis, trabecular measurements, mineral content assessment, and immunofluorescence analysis.

Results

The femoral trochanteric strength after PTH treatment was enhanced in the breaking test (ORX-F_max = 158.7 N vs. ORX + PTH-F_max = 202 N). Stiffness of treated ORX animals reached nearly the levels observed in untreated sham rats. PTH therapy improved the trabecular connectivity, width, and area (ORX-Tb.Ar = 47.79% vs. ORX + PTH-Tb.Ar = 68.47%, P < 0.05) in the proximal femur. The treated rats showed significantly improved mineral content in ashed femurs (ORX-mineral content = 43.73% vs. ORX + PTH-mineral content = 49.49%) when compared to the untreated animals. A comparison of widths of fluorescence bands in cortical bone of the subtrochanteric cross-sections showed a significant increase in oppositions after the PTH therapy.

Conclusions

Our finding supports the hypothesis that PTH therapy seems to be a rational therapy in patients with hypogonadism induced bone loss and improves the bone strength of trochanteric region of rat femur.

Rocchietti March M, Pisani D, Aliberti G (2009) Male osteoporosis. Minerva Endocrinol 34:325–332PubMed

Guggenbuhl P (2009) Osteoporosis in males and females: is there really a difference? Joint Bone Spine 76:595–601PubMedCrossRef

Kamel HK (2005) Male osteoporosis: new trends in diagnosis and therapy. Drugs Aging 22:741–748PubMedCrossRef

Van Tongeren LS, Duncan GG, Kendler DL, Pai H (2009) Implementation of osteoporosis screening guidelines in prostate cancer patients on androgen ablation. J Clin Densitom 12:287–291PubMedCrossRef

Maricic M (2010) Intravenous zoledronic acid: what are the indications for male osteoporosis? Curr Osteoporos Rep 8:4–9PubMedCrossRef

Chlebowski RT, Tagawa T (2009) Early breast and prostate cancer and clinical outcomes (fracture). Oncology (Williston Park) 23:16–20

Gomella LG (2009) Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev Urol 11:52–60PubMed

Partridge NC, Li X, Qin L (2006) Understanding parathyroid hormone action. Ann N Y Acad Sci 1068:187–193PubMedCrossRef

Devogelaer JP, Boutsen Y, Manicourt DH (2010) Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men. Curr Osteoporos Rep 8:154–161PubMedCrossRef

10.

Tezval M, Stuermer EK, Sehmisch S, Rack T, Stary A, Stebener M, Konietschke F, Stuermer KM (2010) Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur. Osteoporos Int 21:251–261PubMedCrossRef

11.

Matsumoto T, Shiraki M, Hagino H, Iinuma H, Nakamura T (2006) Daily nasal spray of hPTH(1–34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporos Int 17:1532–1538PubMedCrossRef

12.

Ishihara A, Sasaki T, Debari K, Furuya R, Kawawa T, Ramamurthy NS, Golub LM (1999) Effects of ovariectomy on bone morphology in maxillae of mature rats. J Electron Microsc (Tokyo) 48:465–469

13.

Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef

14.

Moro-Alvarez MJ, Cabrera JA (2010) Osteoporosis in men. Rev Clin Esp 210:342–349PubMedCrossRef

15.

Eriksen EF (2002) Primary hyperparathyroidism: lessons from bone histomorphometry. J Bone Miner Res 17(Suppl 2):N95–N97PubMed

16.

Gabet Y, Kohavi D, Muller R, Chorev M, Bab I (2005) Intermittently administered parathyroid hormone 1–34 reverses bone loss and structural impairment in orchiectomized adult rats. Osteoporos Int 16:1436–1443PubMedCrossRef

17.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRef

18.

Quirosa Flores S, Varsavsky M, Valle Diaz De La Guardia F, Mijan Ortiz JL, Munoz Torres M, Raya Alvarez E, Zuluaga Gomez A (2010) Secondary hyperparathyroidism in advanced prostate cancer. Endocrinol Nutr 57:100–104PubMedCrossRef

19.

Gomes RR Jr, Buttke P, Paul EM, Sikes RA (2009) Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation. Clin Exp Metastasis 26:641–651PubMedCrossRef

20.

Kaji H, Hisa I, Inoue Y, Naito J, Sugimoto T, Kasuga M (2009) Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis. J Bone Miner Metab 27:76–82PubMedCrossRef

21.

Woratanarat P, Kijkunastian C, Wajanavisit W, Suppaphol S, Woratanarat T, Rajatanavin R, Boonyaratavej N, Suriyawongpaisal P (2009) A comparative study of risk factors of femoral neck and intertrochanteric fracture in Thai men. J Med Assoc Thai 92(Suppl 6):S165–S171PubMed

Title: Effect of parathyroid hormone on hypogonadism induced bone loss of proximal femur of orchiectomized rat
Authors: M. Tezval
G. Serferaz
T. Rack
L. Kolios
S. Sehmisch
U. Schmelz
H. Tezval
K. M. Stuermer
E. K. Stuermer
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 4/2011
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-011-0652-9

At a glance: The STEP trials

Springer Medicine

Effect of parathyroid hormone on hypogonadism induced bone loss of proximal femur of orchiectomized rat

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2011

Does the greater number of lymph nodes removed during standard lymph node dissection predict better patient survival following radical cystectomy?

Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate

Tensor fascia lata flap reconstruction following groin dissection: is it worthwhile?

Gender effect on renal outcome in patients with urothelial carcinoma

Extracellular matrix remodeling in the human gubernaculum during fetal testicular descent and in cryptorchidic children

Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients